[1] |
Gong Sheng, Wang Ning, Li Dan, Li Gang, Liu Yu, Jiang Liangshuang, Yao Xiaojun.
Comparative study of fluorescence staining method and inflation-deflation method for thoracoscopic pulmonary tuberculosis segmentectomy
[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 292-297.
|
[2] |
Yang Haixia, Zhang Xiaoyan, Huang Yi, Li Qiu.
Effective and safety of concurrent intensity-modulated radiotherapy and anti-tuberculosis chemotherapy in patients with active pulmonary tuberculosis comorbid with thoracic tumor
[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 312-321.
|
[3] |
Tan Shouyong.
Research progress on comprehensive treatment beyond antibiotic therapy for nontuberculous mycobacterium pulmonary disease
[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 967-970.
|
[4] |
Ge Jing, Wang Jun, He Yuqi, Nie Wenjuan.
Six cases of pseudomembranous colitis caused by anti-tuberculosis drugs and literature review
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1320-1326.
|
[5] |
Li Xuelian, Jing Wei, Wang Qingfeng, Chu Naihui, Nie Wenjuan.
An all-oral shortened regimen containing new drugs to treat MDR/rifampicin-resistant tuberculosis: three case reports and literature review
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1327-1334.
|
[6] |
Tian Yuan, Jing Wei, Wang Qingfeng, Chu Naihui, Nie Wenjuan.
A case of multiple infections such as multidrug-resistant tuberculosis caused by positive anti-interferon-γ autoantibodies and literature review
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1335-1342.
|
[7] |
Li Cuiping, Chen Pinru, Xue Lijing, Zheng Shengkun.
Nontuberculous mycobacterium parotid lymphadenitis in children: report of 3 cases and literature review
[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1259-1265.
|
[8] |
Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua.
Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update
[J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348.
|
[9] |
Ren Fei, Ma Jinbao, Li Rong, Yang Han, Yang Hong, Wu Yanqin, Yang Xinjun, Dang Liyun.
Efficacy and eligibility of high-dose moxifloxacin short-course regimen for rifampicin-resistant pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 52-59.
|
[10] |
Wang Ni, Huang Fei, Zhu Limei, Zeng Yi, Zhang Ruimei, Geng Hong, Liu Xuefa, Zheng Jiangang, Zong Peilan, Zeng Zhong, Li Jinlan, Cai Cui, Guo Xiaohong, Zhong Yin, Liu Li, Xie Yan, Du Fangfang, Zhou Lin, Cheng Shiming.
Implementation study on promoting the use of anti-tuberculosis fixed-dose combination in provincial and prefecture tuberculosis designated hospitals
[J]. Chinese Journal of Antituberculosis, 2022, 44(9): 927-933.
|
[11] |
AN Hui-ru, WU Xue-qiong.
Interpretation of immunoadjuvant therapy in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition)
[J]. Chinese Journal of Antituberculosis, 2022, 44(6): 539-543.
|
[12] |
LIU Li-qin, XU Zu-hui, HUANG Yi-sheng, YAO Qi-neng, TAN Yun-hong, ZHOU Lin, XIA Yin-yin, LIU Er-yong, HUANG Guo-jun, BAI Li-qiong, CHENG Shi-ming.
Study on the clinical efficacy of a 4-month treatment program for the initial treatment of smear-negative pulmonary tuberculosis with Mycobacterium vaccae Vaccine immune intervention
[J]. Chinese Journal of Antituberculosis, 2022, 44(2): 125-130.
|
[13] |
Jin Long, Wang Lihua, Zhang Xiaolei, Jiang Huailong, Li Xiaonan, Liu Yuqin.
Efficacy and safety of modified all-oral short course chemotherapy in the treatment of multidrug-resistant pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1321-1326.
|
[14] |
Gong Wenping, Mi Jie, Wu Xueqiong.
Immunologically active substances: novel treatment options for tuberculosis and nontuberculous mycobacteriosis
[J]. Chinese Journal of Antituberculosis, 2022, 44(11): 1107-1121.
|
[15] |
Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment/Institute for Tuberculosis Research of the 8th Medical Center of Chinese PLA General Hospital, Editorial Board of Chinese Journal of Antituberculosis , Basic and Clinical Speciality Committees of Tuberculosis Control Branch of China International Exchange and Promotive Association for Medical and Health Care .
Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition)
[J]. Chinese Journal of Antituberculosis, 2022, 44(1): 9-27.
|